Orlynvah Launch Iterum recently launched Orlynvah, the first oral penem antibiotic approved in the US for uncomplicated UTIs. This creates a commercial entry point and potential expansion into broader UTIs and hospital settings. Business development opportunities include hospital formulary access, ID physician engagement, payer conversations for favorable reimbursement, and real world evidence generation to support expansion.

MDR Focus Opportunity Iterum is dedicated to anti-infectives targeting multi drug resistant pathogens, addressing a critical global need. Leverage this positioning to partner with hospitals and government programs on antimicrobial stewardship, clinical trials, and joint development of next generation agents. Opportunities exist to license or co-develop additional assets and to secure preferred supplier status with large healthcare systems.

Global Partnership Potential With an Ireland base and US approved oral product, there is room to pursue EU UK distribution partnerships, manufacturing collaborations, and regional co development deals. Consider CMO manufacturing partnerships and regional distributors to scale supply and accelerate market access, leveraging Orlynvah as a gateway to broader anti infective portfolios.

Commercial Readiness The appointment of a Chief Commercial Officer and active conference presence signals go to market readiness. Sales plays should target infectious disease and urology specialists, hospital networks, and payers, supported by KOL engagement, pricing strategy, and hospital contracting plans to maximize uptake and payer coverage.

Funding & Growth Revenue in the low tens of millions and modest external funding suggest a need for strategic partnerships to fund late stage development and expansion. Propose milestone based licensing, co development agreements, and exclusive distribution deals to accelerate growth while sharing risk with larger pharma or investors.